Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 2 of 7

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in this application.

1. (Previously Presented) Procedure for obtaining 1 1 -(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine, of formula (I)

(I)

or a pharmaceutically acceptable salt thereof, wherein it comprises reaction between compound of formula (II) and a compound of formula (III):

$$\begin{array}{c} & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & & \\ & &$$

Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 3 of 7

in which X means a leaving group and P a protective group of alcohols resistant to alkaline conditions, in the presence of a base, followed by a step of deprotection and, eventually, obtaining a pharmaceutically acceptable salt thereof.

- 2. (Previously Presented) Procedure according to Claim 1, wherein said reaction between said compound of formula (II) and said compound of formula (III) is carried out by phase transfer in the presence of a phase-transfer catalyst.
- 3. (Previously Presented) Procedure according to Claim 2, wherein said phase-transfer catalyst is selected from among tetrabutyl ammonium bisulphate, Aliquat 336, tetrabutyl ammonium iodide, 18-crown-6-ether.
- 4. (Previously Presented) Procedure according to Claim 2, wherein said phase-transfer reaction is carried out in the absence of organic solvent.
- 5. (Previously Presented) Procedure according Claim 1, wherein said base is an alkaline or alkaline-earth organic or inorganic base.
- 6. (Previously Presented) Procedure according to Claim 1, wherein said base is an alkaline or alkaline-earth hydroxide or carbonate.
- 7. (Currently Amended) Procedure according to Claim 6, wherein said base is an alkaline hydroxide in solid form or in aqueous <u>solution form</u>.
- 8. (Currently Amended) Procedure according to Claim 1, wherein X is <u>halogen halopgen</u> or an alkylsulphonyloxy or arylsulphonyloxy group.
- 9. (Currently Amended) Procedure according to Claim 8, wherein X is a mesylate, triflate, nonaflate, nonaflatem 2,2,2-trifluoro-ethane-sulfonate, tosylate, brosylate or nosylate.
- 10. (Previously Presented) Procedure according to Claim 1, wherein said protective group of

Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 4 of 7

alcohols P is of ether type.

- 11. (Previously Presented) Procedure according to Claim 10, wherein said protective group of alcohols P of ether type is selected from tetrahydropyranyl, benzyl and trityl (triphenylmethyl).
- 12. (Previously Presented) Procedure according to Claim 11, wherein said protective group of alcohols P of ether type is trityl.
- 13. (Previously Presented) Procedure according to Claim 1, wherein said step of deprotection includes hydrolysis in acid medium of an intermediate of formula (IV):

(IV)

in which P has the meaning defined in Claim 1.

Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 5 of 7

14. (Previously Presented) Intermediate of formula (IV):

(IV)

in which P is a protective group of alcohols resistant to alkaline conditions.

- 15. (Previously Presented) Intermediate of formula (IV) according to claim 14, wherein said protective group of alcohols P is of ether type.
- 16. (Previously Presented) Intermediate of formula (IV) according to claim 15, wherein said protective group of alcohols P is of ether type is selected from tetrahydropyranyl, benzyl and trityl (triphenylmethyl).
- 17. (Previously Presented) Intermediate of formula (IV) according to claim 15, wherein said protective group of alcohols P of ether type is trityl.